Incidence, procedural management, and clinical outcomes of coronary in‐stent restenosis: Insights from the National VA CART Program

Publisher： John Wiley & Sons Inc

E-ISSN： 1522-726x|91|3|425-433

ISSN： 1522-1946

Source： CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol.91, Iss.3, 2018-02, pp. : 425-433

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impact of high lipoprotein(a) levels on in‐stent restenosis and long‐term clinical outcomes of angina pectoris patients undergoing percutaneous coronary intervention with drug‐eluting stents in Asian population

By  

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (ELECTRONIC), Vol. 42, Iss. 6, 2015-06 ,pp. : 588-595

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Evaluation of Coronary In‐Stent Restenosis Using Dual‐Source Computed Tomography

By  

ECHOCARDIOGRAPHY (ELECTRONIC), Vol. 32, Iss. 11, 2015-11 ,pp. : 1681-1687

John Wiley & Sons Inc

Access to resources Recommend Favorite

KISS for in‐stent restenosis

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 91, Iss. 3, 2018-02 ,pp. : 434-434

John Wiley & Sons Inc

Access to resources Recommend Favorite

Plasma Levels of Interleukin 18, Interleukin 10, and Matrix Metalloproteinase-9 and -137G/C Polymorphism of Interleukin 18 Are Associated with Incidence of In-stent Restenosis After Percutaneous Coronary Intervention

By Liu Wenwei   Liu Yongsheng   Jiang Hua   Ding Xiangwu   Zhu Rui   Li Bin   Zhao Yuqin  

Inflammation, Vol. 36, Iss. 5, 2013-10 ,pp. : 1129-1135

Springer Publishing Company

Access to resources Recommend Favorite

Matrix Metalloproteinases: A Target in In-Stent Restenosis?

By  

Cardiology, Vol. 124, Iss. 1, 2013-01 ,pp. : 49-50

Karger

Access to resources Recommend Favorite